Abstract
The concentration of airborne particulate matters (PM) is related to daily hospital admissions for several pulmonary disorders such as bronchial asthma, acute and chronic bronchiolitis, and pneumonia. Especially, PM with a mass median aerodynamic diameter < or 2.5 μm (PM2.5) is recognized to be more closely associated with respiratory effects and subsequent mortality than that of mass median aerodynamic diameter < or 10 μm (PM10). However, there has been insufficient experimental evidence and their underlying mechanisms to support these epidemiological investigations. In this review, we introduce the adverse effects of PM, particularly, diesel exhaust particles, the main constituents of PM, on several pulmonary diseases, showing our in vivo evidence. Further, we also focus on the effects of nanoparticles, particles less than 100 nm in mass median aerodynamic diameter, on respiratory tract and disorders.
Keywords: Particulate matters, diesel exhaust particles, nanoparticles, acute lung inflammation, allergic asthma
Current Respiratory Medicine Reviews
Title: Airborne Particles in Pulmonary Diseases
Volume: 5 Issue: 2
Author(s): Ken-ichiro Inoue, Hirohisa Takano, Rie Yanagisawa and Toshikazu Yoshikawa
Affiliation:
Keywords: Particulate matters, diesel exhaust particles, nanoparticles, acute lung inflammation, allergic asthma
Abstract: The concentration of airborne particulate matters (PM) is related to daily hospital admissions for several pulmonary disorders such as bronchial asthma, acute and chronic bronchiolitis, and pneumonia. Especially, PM with a mass median aerodynamic diameter < or 2.5 μm (PM2.5) is recognized to be more closely associated with respiratory effects and subsequent mortality than that of mass median aerodynamic diameter < or 10 μm (PM10). However, there has been insufficient experimental evidence and their underlying mechanisms to support these epidemiological investigations. In this review, we introduce the adverse effects of PM, particularly, diesel exhaust particles, the main constituents of PM, on several pulmonary diseases, showing our in vivo evidence. Further, we also focus on the effects of nanoparticles, particles less than 100 nm in mass median aerodynamic diameter, on respiratory tract and disorders.
Export Options
About this article
Cite this article as:
Inoue Ken-ichiro, Takano Hirohisa, Yanagisawa Rie and Yoshikawa Toshikazu, Airborne Particles in Pulmonary Diseases, Current Respiratory Medicine Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339809788189941
DOI https://dx.doi.org/10.2174/157339809788189941 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Management of Stable COPD: An Update
Current Respiratory Medicine Reviews The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Melatonin in Bacterial and Viral Infections with Focus on Sepsis: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Recent Patents on Drug Delivery & Formulation Editorial (Thematic Issue: Nanoinformatics to Organic Synthesis, ADMET Profiling, and Application of Nanomaterials in Medicinal Chemistry, Medicine, and Biotechnology)
Current Topics in Medicinal Chemistry Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Animal Models for Human Asthma: The Perspective of a Clinician
Current Drug Targets Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Review in Pharmacokinetic Models on Corticosteroids
Mini-Reviews in Medicinal Chemistry Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Inflammation Biomarkers in Psychiatry
Current Psychiatry Research and Reviews Fast Dissolving/Disintegrating Dosage Forms: Growth from Immediate Release to Sustained Release and Traditional Medicines
Recent Patents on Drug Delivery & Formulation Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Lactobacillus Rhamnosus Cell Lysate in the Management of Resistant Childhood Atopic Eczema
Inflammation & Allergy - Drug Targets (Discontinued) Serotonin Type-4 (5-HT4) Receptors as Therapeutic Targets: Past and Future Roles of 5-HT4 Receptor Agonists
Current Medicinal Chemistry - Central Nervous System Agents